Antisoma sells US rights to oral fludarabine to Sanofi-Aventis
UK cancer specialist Antisoma has sold the US rights to oral fludarabine, its Food and Drug Administration-approved treatment for chronic lymphocytic leukemia, to French drug major Sanofi-Aventis in exchange for an immediate cash payment of $60.0 million and further amounts totalling $5.0 million. Company chief executive Glyn Edwards said: "the sale of oral fludarabine roughly doubles our cash resources, and will enable us to pursue all our priority programs until at least mid-2011, which is well beyond when we expect key Phase III results for our leading products, ASA404 and AS1413."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze